Bacillus Calmette-Guérin (BCG): mechanism of action in superficial bladder cancer.
Ratliff
T L
TL
Division of Urology, Washington University School of Medicine, St. Louis, Missouri.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D009092:Mucous Membrane / Q000187:drug effects; D001743:Urinary Bladder / Q000187:drug effects*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D005353:Fibronectins; D004317:Doxorubicin